Newly appointed ScinoPharm Taiwan Ltd (台灣神隆) president Tony Su (蘇崇銘) yesterday said that he would oversee the company’s transition amid immense changes in global markets and supply chains.
“My first responsibility at the company would be to oversee continuation of organizational restructuring and cost management,” Su told an earnings conference.
He said that the global market for generic drugs has been reshuffled by rapid consolidation and the company faces increasing challenges as prices trend lower.
Apart from changing its chief financial and research and development officers, there has not been a major shift in the management team, although key executives would take on additional roles to better align them with the company’s objectives, Su said.
Su was previously with Uni-President Enterprises Corp (UPE, 統一企業), a major investor in ScinoPharm.
ScinoPharm, which makes active pharmaceutical ingredients (APIs), as well as providing contract manufacturing and research services, said that it would begin to see profit contribution from a newly approved generic oncology injection that was developed with US-based Sagent Pharmaceutical Inc.
ScinoPharm said that its generic version of anti-thrombotic drug Fondaparinux in March gained approval from the US Food and Drug Administration and is to begin sales in the US in two to three months time.
The anti-thrombotic drug is also expected to gain market approval from Indian authorities and commence sales there this year, the company said.
This year, ScinoPharm has gained regulatory approval in China to supply generic APIs for a treatment for benign prostatic hyperplasia and a generic oncology injectible for myeloid leukemia in the US.
The company has observed a significant shift in China’s API supply chain as Beijing tightens environmental requirements, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) said.
China has been ordering noncompliant manufacturers to shut down, leading to disruptions in the supply and pricing of chemicals, Lin said.
The company has minimized the disruption by importing from other markets, Lin said, adding that China’s new plant inspection regimen and stricter drug license approvals should help push out low-quality API suppliers.
The company reported that net income in the second quarter dipped 3 percent quarterly to NT$131 million (US$4.27 million), although revenue rose 14 percent to NT$986 million on the back of strong sales of colorectal cancer products. Earnings per share (EPS) were NT$0.17.
In the April-to-June period, gross margin and operating margin were 43 percent and 16 percent respectively, up from 39 percent and 14 percent in the previous period.
Overall, net income in the first half rose 5 percent annually to NT$267 million, or EPS of NT$0.34, while sales gained 4 percent to reach NT$1.85 billion.
Real estate agent and property developer JSL Construction & Development Co (愛山林) led the average compensation rankings among companies listed on the Taiwan Stock Exchange (TWSE) last year, while contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) finished 14th. JSL Construction paid its employees total average compensation of NT$4.78 million (US$159,701), down 13.5 percent from a year earlier, but still ahead of the most profitable listed tech giants, including TSMC, TWSE data showed. Last year, the average compensation (which includes salary, overtime, bonuses and allowances) paid by TSMC rose 21.6 percent to reach about NT$3.33 million, lifting its ranking by 10 notches
Popular vape brands such as Geek Bar might get more expensive in the US — if you can find them at all. Shipments of vapes from China to the US ground to a near halt last month from a year ago, official data showed, hit by US President Donald Trump’s tariffs and a crackdown on unauthorized e-cigarettes in the world’s biggest market for smoking alternatives. That includes Geek Bar, a brand of flavored vapes that is not authorized to sell in the US, but which had been widely available due to porous import controls. One retailer, who asked not to be named, because
SEASONAL WEAKNESS: The combined revenue of the top 10 foundries fell 5.4%, but rush orders and China’s subsidies partially offset slowing demand Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) further solidified its dominance in the global wafer foundry business in the first quarter of this year, remaining far ahead of its closest rival, Samsung Electronics Co, TrendForce Corp (集邦科技) said yesterday. TSMC posted US$25.52 billion in sales in the January-to-March period, down 5 percent from the previous quarter, but its market share rose from 67.1 percent the previous quarter to 67.6 percent, TrendForce said in a report. While smartphone-related wafer shipments declined in the first quarter due to seasonal factors, solid demand for artificial intelligence (AI) and high-performance computing (HPC) devices and urgent TV-related orders
STILL LOADED: Last year’s richest person, Quanta Computer Inc chairman Barry Lam, dropped to second place despite an 8 percent increase in his wealth to US$12.6 billion Staff writer, with CNA Daniel Tsai (蔡明忠) and Richard Tsai (蔡明興), the brothers who run Fubon Group (富邦集團), topped the Forbes list of Taiwan’s 50 richest people this year, released on Wednesday in New York. The magazine said that a stronger New Taiwan dollar pushed the combined wealth of Taiwan’s 50 richest people up 13 percent, from US$174 billion to US$197 billion, with 36 of the people on the list seeing their wealth increase. That came as Taiwan’s economy grew 4.6 percent last year, its fastest pace in three years, driven by the strong performance of the semiconductor industry, the magazine said. The Tsai
RSS